Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer
- 31 May 2002
- journal article
- Published by Elsevier in European Urology Supplements
- Vol. 1 (2), 15-23
- https://doi.org/10.1016/s1569-9056(02)00005-2
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Phase II Study of Estramustine and Vinorelbine in Hormone-Refractory Prostate Carcinoma PatientsActa Oncologica, 1998
- Oral estramustine and oral etoposide for hormone-refractory prostate cancerUrology, 1997
- Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell linesPublished by Wiley ,1997
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Multidrug Chemotherapy in the Treatment of Non-Elderly Patients with Hormone-Refractory Prostatic CarcinomaEuropean Urology, 1996
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.Journal of Clinical Oncology, 1994
- Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerCancer, 1993
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic CancerJournal of Urology, 1992